Safety, biodistribution, and dosimetry of 123I-IMPY: a novel amyloid plaque-imaging agent for the diagnosis of Alzheimer's disease.

@article{Newberg2006SafetyBA,
  title={Safety, biodistribution, and dosimetry of 123I-IMPY: a novel amyloid plaque-imaging agent for the diagnosis of Alzheimer's disease.},
  author={Andrew B Newberg and Nancy A. Wintering and Karl Ploessl and John Hochold and Michael G. Stabin and Marianne Watson and Daniel M. Skovronsky and C. M. Clark and M. -P. Kung and Hank F Kung},
  journal={Journal of nuclear medicine : official publication, Society of Nuclear Medicine},
  year={2006},
  volume={47 5},
  pages={748-54}
}
UNLABELLED (123)I-IMPY (6-iodo-2-(4'-dimethylamino-)phenyl-imidazo[1,2-a]pyridine) is a novel radiopharmaceutical that selectively binds to Alzheimer's disease (AD) amyloid plaques. As a first step toward validating this radiopharmaceutical as an imaging biomarker for AD, we measured the whole-body biokinetics and radiation dosimetry of (123)I-IMPY in AD patients and cognitively normal control subjects. The pharmacologic safety profile of the compound was simultaneously assessed. METHODS The… CONTINUE READING
30 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 30 extracted citations

Similar Papers

Loading similar papers…